Sign in Subscribe

Archive

A collection of 699 issues

Latest

Envafolimab plus chemoradiation improves pathologic complete response in MSS rectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Envafolimab plus chemoradiation improves pathologic complete response in MSS rectal cancer An interim analysis of the phase III PRECAM-R trial found that adding subcutaneous PD-L1 blocker envafolimab to short-course radiotherapy and CAPEOX improved pathologic complete response to 44.8% in patients with

CRC Research Update — September 11, 2026

Today's colorectal cancer research highlights

Lynch syndrome diagnosis rate in China far below expected prevalence

Skip to content The CRC Digest Lynch syndrome diagnosis rate in China far below expected prevalence A national survey of 81 physicians from 81 Chinese hospitals found a Lynch syndrome diagnosis rate of only 0.83% versus the expected 2-3%, despite 95.1% of hospitals offering dMMR immunohistochemistry. (Familial Cancer)

Encorafenib, cetuximab, and nivolumab rechallenge succeeds in BRAF V600E mCRC case

Skip to content The CRC Digest Encorafenib, cetuximab, and nivolumab rechallenge succeeds in BRAF V600E mCRC case A case report from the AGMT mCRC Registry describes successful rechallenge with encorafenib and cetuximab combined with nivolumab in a patient with BRAF V600E mutated, mismatch-repair-proficient metastatic colorectal cancer. (Clinical Colorectal Cancer) This

Machine learning may enable early detection in under-50 population

Skip to content The CRC Digest Machine learning may enable early detection in under-50 population A review highlights that early-onset colorectal cancer incidence is rising fastest in the population below guideline-endorsed screening age, and blood-based liquid biopsy combined with machine learning offers a plausible route to early detection. (Frontiers in

Network analysis reveals symptom cluster stability during adjuvant chemotherapy

Skip to content The CRC Digest ♥ LIVING WITH CRC Network analysis reveals symptom cluster stability during adjuvant chemotherapy A prospective longitudinal study used network temperature to characterize temporal changes in symptom clusters among postoperative colorectal cancer patients receiving adjuvant chemotherapy, finding that symptom burden compromises quality of life. (Supportive Care

AZUR-4 Phase II trial tests neoadjuvant dostarlimab plus CAPEOX in MSS stage III colon cancer

Skip to content The CRC Digest ◆ TRIAL DATA AZUR-4 Phase II trial tests neoadjuvant dostarlimab plus CAPEOX in MSS stage III colon cancer This randomized Phase II study compares neoadjuvant dostarlimab plus CAPEOX versus CAPEOX alone in previously untreated T4N0 or stage III mismatch repair proficient/microsatellite stable resectable colon

ctDNA-guided rechallenge with cetuximab plus irinotecan shows activity in RAS/BRAF wild-type mCRC

Skip to content The CRC Digest ▸ TREATMENT ctDNA-guided rechallenge with cetuximab plus irinotecan shows activity in RAS/BRAF wild-type mCRC A Phase II trial enrolled patients with RAS/BRAF wild-type metastatic colorectal cancer who had progressed on prior cetuximab-based therapy, using circulating tumor DNA testing to select patients for rechallenge

Blood test combining cfDNA fragmentomics and methylation markers detects precancerous lesions

Skip to content The CRC Digest ▪ SCREENING Blood test combining cfDNA fragmentomics and methylation markers detects precancerous lesions A study of 380 CRC patients, 121 individuals with precancerous lesions, and 506 healthy controls found that adding methylation analysis of SEPT9 and HS3ST2 to cfDNA fragmentomics improved detection of precancerous lesions,

CRC Research Update — September 10, 2026

Today's colorectal cancer research highlights